CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
Carboplatin +3 moredrug
Likely dose
Pemetrexed 500 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01263782
NCT01263782Phase 2Completed
CompareCT.gov

BATTLE-FL: A Biomarker-Integrated Study in Patients With Advanced Non-Small Cell Lung Cancer Treated in the Front-Line (FL) Setting

M.D. Anderson Cancer Center·interventional·Posted Dec 21, 2010·Updated May 15, 2019

In Brief

A Phase 2 clinical trial evaluating Carboplatin, Pemetrexed, and 2 other interventions for Lung Cancer. Completed, enrolled 64 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if knowing biomarker status can help researchers find better treatment combinations for patients with advanced NSCLC. Researchers want to use biomarker status to decide what drug (bevacizumab, or cixutumumab) to give in combination with carboplatin and pemetrexed. The safety of these drug combinations will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsEli Lilly and Company, Genentech, Inc.

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 21, 2010
Enrollment StartMay 17, 2011
Primary CompletionAug 15, 2017
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 15.5 years ago

Interventions

Carboplatindrug

AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.

Pemetrexeddrug

500 mg/m2 by vein on day 1 of each 21 day cycle.

Bevacizumabdrug

15 mg/kg by vein on day 1 of each 21 day cycle.

Cixutumumabdrug

20 mg/kg by vein on day 1 of each 21 day cycle.